OncoEthix Doses First Patient in Its Phase I Trial of OTX015, a BET Bromodomain Inhibitor for the Treatment of Hematologic Malignancies
Published: Jan 31, 2013
LAUSANNE, Switzerland--(BUSINESS WIRE)--OncoEthix, the Swiss-based specialist in oncology drug development, announces progress in its Phase I study of OTX015, a novel BET bromodomain inhibitor, with the first dosing of a patient. OTX015 is a synthetic orally administered small molecule which targets BET bromodomain proteins 2/3/4, which are considered potential cancer targets because of their pivotal role in regulating the transcription of growth-promoting and cell cycle regulators, especially c-MYC. Phase I trials of OTX015 in healthy volunteers have already been completed.